3 However, when stratified by histopathological subtype, a striking difference emerged: BB use was independently associated with improved overall survival and recurrence-free survival in patients with diffuse-type gastric cancer (DGC), whereas a negative trend was observed in intestinal-type gastric cancer.
← all excerpts
ASO Author Reflections: The Role of Beta-Blockers in Gastric Cancer-A Pathway to Personalized Therapy?
1
—
—